- Acceleron expects to report approximately
$19.3 million in royalty revenue for Q3 2020 from approximately $96
million in net sales of REBLOZYL® (luspatercept-aamt) as reported
by Bristol Myers Squibb -
- Acceleron will report its full third quarter
2020 financial and operating results after the close of U.S.
financial markets today, November 5, 2020, with its webcast and
conference call starting at 5:00 p.m. EST -
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company
dedicated to the discovery, development, and commercialization of
TGF-beta superfamily therapeutics to treat serious and rare
diseases, today announced net sales of REBLOZYL®
(luspatercept-aamt) as reported by its global collaborator, Bristol
Myers Squibb, were approximately $96 million for the third quarter
ended September 30, 2020.
Acceleron expects to report royalty revenue of approximately
$19.3 million from net sales of REBLOZYL in the third quarter ended
September 30, 2020. This compares with approximately $11.1 million
in royalty revenue from approximately $55.0 million of net sales of
REBLOZYL for the second quarter ended June 30, 2020.
Acceleron will announce its full third quarter 2020 financial
and operating results after the close of the U.S. financial markets
today, November 5, 2020.
The preliminary unaudited revenue estimate for the quarter ended
September 30, 2020 included in this release is the responsibility
of management and is subject to the completion of the Company’s
customary quarter-end financial closing procedures, including
management’s review and finalization and review procedures by the
Company’s independent registered public accounting firm, which have
not yet been completed. During the course of the Company’s review
process, items may be identified that would require it to make
adjustments, which could result in material changes to the
Company’s preliminary unaudited estimated financial results.
Consequently, this revenue estimate should not be viewed as a
substitute for the Company’s earnings release and Quarterly Report
on Form 10-Q.
Conference Call and Webcast
The Company will host a webcast and conference call to discuss
its third quarter 2020 financial results and provide an update on
recent corporate activities on November 5, 2020, at 5:00 p.m.
EST.
The webcast will be accessible under "Events &
Presentations" in the Investors & Media page of the Company’s
website at acceleronpharma.com. Individuals can participate in the
conference call by dialing 877-312-5848 (domestic) or 253-237-1155
(international) and referring to the “Acceleron Third Quarter 2020
Earnings Call.”
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its commercialization, research, and
development efforts in hematologic and pulmonary diseases. In
hematology, REBLOZYL® (luspatercept-aamt) is the first and only
erythroid maturation agent approved in the United States, Europe,
and Canada for the treatment of anemia in certain blood disorders.
REBLOZYL is part of a global collaboration partnership with Bristol
Myers Squibb. The Companies co-promote REBLOZYL in the United
States and are also developing luspatercept for the treatment of
anemia in patient populations of MDS, beta-thalassemia, and
myelofibrosis. In pulmonary, Acceleron is developing sotatercept
for the treatment of pulmonary arterial hypertension (PAH), having
recently reported positive topline results of the PULSAR Phase 2
trial. The Company is currently planning multiple Phase 3 trials
with the potential to support its long-term vision of establishing
sotatercept as a backbone therapy for patients with PAH at all
stages of the disease.
For more information, please visit acceleronpharma.com. Follow
Acceleron on social media: @AcceleronPharma and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements about the
Company's financial results. The words "anticipate," "believe,"
"could," "estimate," "expect," "goal," "intend," "may," "plan,"
"potential," "project," "should," "target," "will," "would," and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to, that preclinical
testing of the Company's compounds and data from clinical trials
may not be predictive of the results or success of other clinical
trials, that regulatory approval of the Company’s compounds in one
indication or country may not be predictive of approval in another
indication or country, that the development of the Company’s
compounds may take longer and/or cost more than planned or
accelerate faster than currently expected, that the Company or its
collaboration partner, Bristol Myers Squibb (“BMS”), may be unable
to successfully complete the clinical development of the Company’s
compounds, that the Company or BMS may be delayed in initiating,
enrolling or completing any clinical trials, and that the Company’s
compounds may not receive regulatory approval or become
commercially successful products. These and other risks and
uncertainties are identified under the heading “Risk Factors”
included in the Company’s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q, and other filings that the Company
has made and may make with the SEC in the future.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions, and projections with respect to future events, and the
Company does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201105005579/en/
Acceleron Pharma Inc. Investors: Jamie Bernard, IRC,
617-649-9650 Associate Director, Investor Relations Media: Matt
Fearer, 617-301-9557 Director, Corporate Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024